[1]黄文鹏,杨琦,陈钊,等.分子核医学在嵌合抗原受体T细胞免疫治疗的应用进展[J].中国医学物理学杂志,2023,40(9):1057-1063.[doi:DOI:10.3969/j.issn.1005-202X.2023.09.001]
HUANG Wenpeng,YANG Qi,CHEN Zhao,et al.Advances in application of molecular nuclear medicine in chimeric antigen receptor T cell immunotherapy[J].Chinese Journal of Medical Physics,2023,40(9):1057-1063.[doi:DOI:10.3969/j.issn.1005-202X.2023.09.001]
点击复制
分子核医学在嵌合抗原受体T细胞免疫治疗的应用进展(
)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- 卷:
-
40卷
- 期数:
-
2023年第9期
- 页码:
-
1057-1063
- 栏目:
-
医学放射物理
- 出版日期:
-
2023-09-26
文章信息/Info
- Title:
-
Advances in application of molecular nuclear medicine in chimeric antigen receptor T cell immunotherapy
- 文章编号:
-
1005-202X（2023）09-1057-07
- 作者:
-
黄文鹏; 杨琦; 陈钊; 邱永康; 宋乐乐; 范岩; 康磊
-
北京大学第一医院核医学科， 北京 100034
- Author(s):
-
HUANG Wenpeng; YANG Qi; CHEN Zhao; QIU Yongkang; SONG Lele; FAN Yan; KANG Lei
-
Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
-
- 关键词:
-
分子核医学; 免疫疗法; 免疫成像; 嵌合抗原受体; 综述
- Keywords:
-
Keywords: molecular nuclear medicine immunotherapy immunoimaging chimeric antigen receptor review
- 分类号:
-
R392；R811.1
- DOI:
-
DOI:10.3969/j.issn.1005-202X.2023.09.001
- 文献标志码:
-
A
- 摘要:
-
嵌合抗原受体T细胞（CAR-T）疗法作为一种新型、精准靶向的免疫疗法，给血液系统恶性肿瘤的治疗带来了革命性的变化。基于放射性核素的PET、SPECT等分子核医学技术具有非侵入性、长期动态、实时监测活体水平内的分子靶标评价的独特优势，有助于优化输注CAR-T细胞的时机、剂量以及避免潜在的生物毒性，并对指导CAR-T疗法的研发起重要作用。本文对基于放射性核素的分子核医学在CAR-T细胞治疗中的监测和疗效评估应用进行综述，其中一些有前景的分子探针的临床转化有助于监测CAR-T细胞的活性、生物分布和靶向肿瘤部位的传输。
- Abstract:
-
Abstract: Chimeric antigen receptor T cell (CAR-T) therapy as a novel and precision-targeted immunotherapy has revolutionized the treatment of hematologic malignancies. Molecular nuclear medicine technologies such as radionuclide-based PET and SPECT have the unique advantages of non-invasive, long-term dynamic, real-time monitoring of molecular targets at the in vivo level, which are conducive to optimize the timing and dose of CAR-T cell infusion and avoid potential biotoxicity, and play an important role in guiding the development of CAR-T therapy. A review on the application of radionuclide-based molecular nuclear medicine in the monitoring and efficacy assessment of CAR-T therapy is provided. The clinical application of some promising molecular probes helps to monitor CAR-T cell activity, biodistribution and delivery to targeted tumor sites.
备注/Memo
- 备注/Memo:
-
【收稿日期】2023-03-13
【基金项目】国家自然科学基金（82171970, 81871385）；北京市杰出青年项目（JQ21025）；北大医学青年科技创新发展平台青年培育基金（BMU2022PY006）；北京大学临床医学+X青年项目（PKU2021LCXQ023）
【作者简介】黄文鹏，在读博士，研究方向：肿瘤免疫PET显像及诊疗一体化，E-mail: hwpeng19950930@163.com
【通信作者】康磊，副教授，副主任医师，博士生导师，研究方向：肿瘤免疫PET显像及诊疗一体化，E-mail: kanglei@bjmu.edu.cn
更新日期/Last Update:
2023-09-26